Management of Staphylococcus aureus Infections
For Staphylococcus aureus infections, management depends critically on whether the infection is methicillin-susceptible (MSSA) or methicillin-resistant (MRSA), the anatomic site involved, and whether complications are present.
Initial Approach: Determine Methicillin Susceptibility
Start empiric therapy with vancomycin or daptomycin while awaiting culture results, particularly in areas with high MRSA prevalence 1. Once susceptibilities return:
- MSSA: Switch immediately to cefazolin or an antistaphylococcal penicillin (nafcillin/oxacillin) - these beta-lactams are superior to vancomycin for MSSA 2, 1
- MRSA: Continue vancomycin, daptomycin, or use ceftobiprole 1
Skin and Soft Tissue Infections (SSTI)
Simple Cutaneous Abscess
Incision and drainage alone is the primary treatment 3, 4. Antibiotics are only needed if:
- Multiple sites of infection or rapid progression
- Associated cellulitis present
- Systemic illness signs (fever, tachycardia)
- Immunocompromised or extremes of age
- Difficult drainage location (face, hand, genitalia)
- Failed I&D alone 3, 4
Purulent Cellulitis (with drainage but no drainable abscess)
Empiric MRSA coverage is required 3, 4:
Outpatient oral options (5-10 days):
- Clindamycin 300-450 mg TID
- TMP-SMX 1-2 double-strength tablets BID
- Doxycycline or minocycline 100 mg BID
- Linezolid 600 mg BID 3, 4
If streptococcal coverage also needed: add amoxicillin to TMP-SMX or tetracycline, or use clindamycin or linezolid alone 3, 4.
Nonpurulent Cellulitis
Treat for beta-hemolytic streptococci first with a beta-lactam (e.g., cefazolin) 3, 4. Only add MRSA coverage if patient fails to respond or has systemic toxicity 4.
Complicated SSTI (hospitalized patients)
Requires surgical debridement plus IV antibiotics for 7-14 days 3, 4:
IV options:
- Vancomycin 30-60 mg/kg/day divided
- Linezolid 600 mg IV/PO BID
- Daptomycin 4 mg/kg IV daily
- Telavancin 10 mg/kg IV daily
- Clindamycin 600 mg IV TID (if susceptible) 3, 4
Pediatric considerations: Vancomycin is first-line. Clindamycin 10-13 mg/kg/dose IV q6-8h can be used if clindamycin resistance <10% and patient is stable 3, 4. Avoid tetracyclines in children <8 years 3, 4.
Bacteremia
All Patients with S. aureus Bacteremia Must Have:
- Blood cultures repeated 2-4 days after initial positive to document clearance 4
- Transthoracic echocardiography (TTE) - all patients 4, 1
- Transesophageal echocardiography (TEE) if high-risk: persistent bacteremia >48 hours, persistent fever, implantable cardiac devices, or metastatic infection 4, 1
- Source control: Remove infected catheters/devices, drain abscesses 4, 1
Uncomplicated Bacteremia
Defined as: negative follow-up cultures at 2-4 days, defervescence within 72 hours, no endocarditis, no prostheses, no metastatic infection 4, 5.
Treatment duration: Minimum 14 days 4, 6, 7. While recent data suggest shorter courses may be considered, at least 14 days is recommended to prevent relapse, which occurred significantly more with <14 days (7.9% vs 0%) 7.
Antibiotic choice:
Complicated Bacteremia
4-6 weeks of therapy required 4, 5. Do NOT add gentamicin or rifampin routinely 4.
Infective Endocarditis
6 weeks of IV therapy 4:
- MRSA: Vancomycin or daptomycin 6 mg/kg IV daily (some experts use 8-10 mg/kg) 4
- Do NOT add gentamicin or rifampin to vancomycin for native valve endocarditis 4
Prosthetic valve endocarditis: Vancomycin + rifampin 300 mg PO q8h + gentamicin 1 mg/kg IV q8h for 6 weeks 5.
Pneumonia
For severe community-acquired pneumonia (ICU admission, necrotizing/cavitary infiltrates, or empyema), empiric MRSA coverage is required 3.
Treatment for 7-21 days depending on extent 4, 3:
- Adults: Vancomycin or linezolid 600 mg IV/PO BID 4, 3
- Pediatrics: Vancomycin first-line; clindamycin 10-13 mg/kg/dose IV q6-8h if stable and resistance <10% 4, 3
If empyema present: Antibiotics PLUS drainage procedures 4, 3.
Osteomyelitis
Surgical debridement is mainstay - perform whenever feasible 4.
Minimum 8 weeks of therapy 4, 5:
Parenteral options:
Oral options (can use initially or after IV):
Consider adding rifampin 600 mg daily or 300-450 mg BID after bacteremia clears 4, 5. Some experts recommend additional 1-3 months of oral rifampin-based combination therapy 4.
Imaging: MRI with gadolinium is preferred; ESR/CRP may guide response 4.
Septic Arthritis
Joint drainage/debridement always required 4.
Treatment for 3-4 weeks 5:
- Vancomycin 30-60 mg/kg/day IV
- Alternatives: Daptomycin 6 mg/kg IV daily, linezolid 600 mg BID, TMP-SMX + rifampin 5
CNS Infections
Meningitis
- Vancomycin 30-60 mg/kg/day IV (some recommend adding rifampin 600 mg daily) 4, 5
- Alternatives: Linezolid 600 mg IV/PO BID or TMP-SMX 5 mg/kg IV q8-12h 4
If shunt infection: Remove shunt; don't replace until CSF cultures repeatedly negative 4.
Brain Abscess, Subdural Empyema, Spinal Epidural Abscess
Neurosurgical drainage required 4.
- Vancomycin 30-60 mg/kg/day IV (consider adding rifampin 600 mg daily) 4, 5
- Alternatives: Linezolid 600 mg IV/PO BID or TMP-SMX 5 mg/kg IV q8-12h 4
Critical Pitfalls to Avoid
- Never use vancomycin for MSSA when beta-lactams are available - outcomes are inferior 2, 1
- Do not use rifampin as monotherapy for any SSTI 3, 4
- Do not routinely add gentamicin or rifampin to vancomycin for uncomplicated bacteremia or native valve endocarditis 4
- Do not treat simple abscesses with antibiotics alone - I&D is primary treatment 3, 4
- Do not use tetracyclines in children <8 years 3, 4, 8
- Always obtain follow-up blood cultures at 2-4 days to document clearance in bacteremia 4, 1
- Always perform echocardiography in all patients with S. aureus bacteremia 4, 1